CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro - PubMed (original) (raw)
. 2016 Jan 14;35(2):241-50.
doi: 10.1038/onc.2015.78. Epub 2015 Mar 30.
Affiliations
- PMID: 25823028
- DOI: 10.1038/onc.2015.78
CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro
G Xi et al. Oncogene. 2016.
Retraction in
- CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G, Hayes E, Lewis R, Ichi S, Mania-Farnell B, Shim K, Takao T, Allender E, Mayanil CS, Tomita T. Xi G, et al. Oncogene. 2016 Oct 20;35(42):5576. doi: 10.1038/onc.2016.64. Epub 2016 Sep 5. Oncogene. 2016. PMID: 27593924 No abstract available.
Abstract
Chemotherapy is an adjuvant treatment for glioblastomas, however, chemotherapy remains palliative because of the development of multidrug resistance (MDR). Following prolonged chemotherapy, MDR protein 1 (MDR1) and CD133 increase in recurrent glioblastomas. CD133 positive (CD133+) glioma cancer stem-like cells (GCSCs) markedly promote drug resistance and exhibit increased DNA damage repair capability; thus they have a key role in determining tumor chemosensitivity. Although CD133, DNA-dependent protein kinase (DNA-PK), and MDR1 are elevated in CD133+ GCSCs, the relationship among these molecules has not been elucidated. In this study, MDR glioblastoma cell lines were created in response to prolonged doxorubicin chemotherapy. CD133, DNA-PK and MDR1 were markedly elevated in these cells. CD133 and DNA-PK may increase MDR1 via the phosphatidylinositol-3-kinase (PI3K)-Akt signal pathway. PI3K downstream targets Akt and nuclear factor (NF)-κB, which interacts with the MDR1 promoter, were also elevated in these cells. Downregulation of CD133 and DNA-PK by small interfering RNA, or inhibition of PI3K or Akt, decreased Akt, NF-κB and MDR1 expression. The results indicate that CD133 and DNA-PK regulate MDR1 through the PI3K- or Akt-NF-κB signal pathway. Consequently, a novel chemotherapeutic regimen targeting CD133 and DNA-PK in combination with traditional protocols may increase chemotherapeutic efficacy and improve prognosis for individuals who present with glioblastoma.
References
- Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
- J Clin Invest. 2013 Oct;123(10):4131-3 - PubMed
- Mol Cell Biochem. 2010 Jul;340(1-2):265-73 - PubMed
- J Biol Chem. 2007 Jul 20;282(29):21206-12 - PubMed
- Cell Mol Neurobiol. 2009 Sep;29(6-7):845-58 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials